ART27.13

The first patient has been treated in the trial of a new drug that might help people suffering from mesothelioma-related weight loss. The drug is a synthetic cannabinoid called ART27.13. A cannabinoid is a compound that acts on the CB1 and CB2 receptors of the endocannabinoid system. There are a number of cannabinoid drugs on the market. But several of them have significant side effects, including effects on the brain.  Preclinical data on ART27.13 suggest that it may stimulate the appetite and counter mesothelioma-related weight loss with fewer unwanted side effects. The Cancer Appetite Recovery Study (CAReS) is a Phase I trial to test it in people. The Danger of Mesothelioma-Related Weight Loss Over 60 percent of late-stage cancer patients…